Issue 3/2023
Content (14 Articles)
HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study
Samia kada Mohammed, Oumar Billa, Sylvain Ladoire, Clementine Jankowski, Isabelle Desmoulins, Marie-Laure Poillot, Charles Coutant, Françoise Beltjens, Sandrine Dabakuyo, Laurent Arnould
Prognostic effect of subsequent childbirth after the diagnosis of breast cancer using propensity score matching analysis
Tomohiro Ochi, Atsushi Yoshida, Osamu Takahashi, Yuka Kajiura, Junko Takei, Naoki Hayashi, Hiroyuki Takei, Hideko Yamauchi
HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC
Jing-Jing Li, Yue Yu, Jie Ge
Identification of prognostic genes signature and construction of ceRNA network in pirarubicin treatment of triple-negative breast cancer
Jiulong Ma, Fengjun Wang, Chen Chen, Jiahua Ji, Peng Huang, Dexian Wei, Yang Zhang, Liqun Ren
Construction and characterization of a cuproptosis- and immune checkpoint-based LncRNAs signature for breast cancer risk stratification
Yan Li, Feiyang Na, Jianying Pei
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)
Shigeru Imoto, Kun Wang, Xi-wen Bi, Guangyu Liu, Young-Hyuck Im, Seock-Ah Im, Sung Hoon Sim, Takayuki Ueno, Manabu Futamura, Masakazu Toi, Yasuhiro Fujiwara, Sung Gwe Ahn, Jeong Eon Lee, Yeon Hee Park, Shintaro Takao, Mari Saito Oba, Yuko Kitagawa, Masahiko Nishiyama
Characterization of protein-based risk signature to predict prognosis and evaluate the tumor immune environment in breast cancer
Xin Qing, Chunlei Yuan, Ke Wang
ER–/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor
Christine Song, Ayse Tuba Kendi, Ji Yeon Shim, Dawa Jung, Pil Soo Kang, Val J. Lowe, SeungBaek Lee
Dynamic network biomarker to determine the critical point of breast cancer stage progression
Fa Jiang, Lifeng Yang, Xiong Jiao
Severity and risk factors of interval breast cancer in Queensland, Australia: a population-based study
Kou Kou, Jessica Cameron, Philippa Youl, Chris Pyke, Suzanne Chambers, Jeff Dunn, Joanne F. Aitken, Peter D. Baade
Construction of a prognostic risk assessment model for HER2 + breast cancer based on autophagy-related genes
Fan Wang, Linghui Fang, Bifei Fu, Chen Fan
Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within breast cancer subtypes and stages among older women: a SEER-Medicare analysis
Hanxi Zhang, Jamie C. Barner, Leticia R. Moczygemba, Karen L. Rascati, Chanhyun Park, Dhatri Kodali
Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region
Nobumoto Tomioka, Kanako C. Hatanaka, Dai Okuyama, Ken-ichi Watanabe, Mitsugu Yamamoto, Hideki Maeda, Hanae Tachikawa, Sayuri Kuwahara, Ai Shimizu, Hiroaki Suzuki, Yutaka Hatanaka, Masato Takahashi
Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2)
Kenji Tamura, Toru Mukohara, Kan Yonemori, Yumiko Kawabata, Xavier Nicolas, Tomoyuki Tanaka, Hiroji Iwata